EFFECT OF CONCURRENT CHEMORADIOTHERAPY ON PERIPHERAL BLOOD LYMPHOCYTES, CYTOKINES, AND GUT MICROBIOTA IN PATIENTS WITH PELVIC TUMOR

Objective To investigate the effect of concurrent chemoradiotherapy on immune function, inflammatory state, and gut microbiota in patients with pelvic tumor. Methods Peripheral blood and stool samples were collected before and after concurrent chemoradiotherapy from 60 patients with pelvic tumor who were treated in Qingdao Central Hospital from July 2021 to December 2022. Flow cytometry was used to measure the levels of peripheral blood lymphocyte subsets and cytokines, and quantitative real-time PCR was used to measure the number of Fusobacterium nucleatum, Bifidobacterium, Lactobacillus acidophilus, and Streptococcus in stool. Each index was compared in terms of change before and after concurrent chemoradiotherapy, and their correlation with treatment outcome was analyzed. Results After concurrent chemoradiotherapy, the patients with pelvic tumor had significant reductions in the percentages of peripheral blood CD3+CD8+ and CD3-CD19+ cells and the level of interleukin-10 (t=2.571-2.995,P